Study population and disposition
colorectal cancer, pancreatic cancer, breast cancer
COLORECTAL CANCER, PANCREATIC CANCER, BREAST CANCER
Between January 8, 2019 and December 8, 2020, a total of 17 patients received one or more doses of NEO-201. The demographics of patients enrolled are listed in Table Patient demographics and baseline characteristicsPrior to treatment with NEO-201, ten and six patients with colorectal cancer had received anti-VEGF and anti-EGFR directed therapy respectively, and one patient had previously received an immune checkpoint inhibitor (pembrolizumab). Almost all (10/11) patients with colorectal cancer were microsatellite stable. Of the patients with pancreatic cancer, two had received immune checkpoint inhibitors (one pembrolizumab and one ipilimumab + nivolumab) prior to receiving NEO-201. Both patients with breast cancer were treated with anti-estrogen therapy (fulvestrant) and one with ipilimumab + nivolumab prior to receiving NEO-201. One patient with pancreatic cancer and four patients with colorectal cancer showed mutations in the KRAS gene. TMB status was known in only 4 patients: one patient with pancreatic cancer, one patient with breast cancer and one patient with colorectal cancer had intermediate TMB status, while one patient with colorectal cancer showed low TMB status. All patients tested (one with colorectal, one with breast, one with pancreatic cancer) were negative for PDL-1. A panel of all gene alterations recorded for each patient is provided in Supplementary Table 